Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

A modeling study looked at how anticipated cuts to international HIV funding would affect the rate of new cases and ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

The Center in Asbury Park wants people to "Come Early, Stand Proud, and Walk Strong" on May 4 for the New Jersey AIDS Walk ...

The Trump Administration has gutted many areas of healthcare funding and research, especially in infectious diseases. One ...

“Trump ’47 should not allow Trump ’45’s massive public health achievement to be cancelled — especially when that legacy will ...

Young people still face high HIV risks despite PrEP Learn why prevention efforts must center Gen Z for a healthier future.

A new report shows a sharp rise in STIs in Houston and Harris County, with the city's rates now exceeding statewide averages ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Long-acting injectable HIV treatment leads to rectal shedding in a small proportion of patients with HIV, independent of the ...

Moving misbranded and adulterated HIV drugs from the black market to retail pharmacies and HIV patients was a $60 million ...